Impaired glucose tolerance (IGT) represents one of the earliest stages of glucose dysregulation and is associated with macrovascular disease, retinopathy, and microalbuminuria, but whether IGT causes neuropathy is unclear.
neuropathy, with a significant reduction in intraepidermal nerve fiber density (IENFD) and minimal large-fiber involvement in subjects with IGT (5) .
Corneal confocal microscopy (CCM), a novel surrogate measure of small-fiber neuropathy, has been shown to detect early small-fiber damage in diabetic patients (6, 7) . The purpose of this study was to undertake a comprehensive assessment of neuropathy in subjects with IGT using symptoms and neurological deficits, neurophysiology, quantitative sensory testing, and in particular, skin biopsy and CCM, as sensitive measures of small-fiber neuropathy.
RESEARCH DESIGN AND METHODS

Study Subjects
The study comprised 37 subjects aged 30-75 years with IGT (oral glucose tolerance test: 2-h glucose = 7.8-11.1 mmol/L) and 20 age-matched control subjects with glucose tolerance within normal limits. Subjects with any other cause of peripheral neuropathy, active corneal disease, surgery, or chronic contact lens use were excluded. This research adhered to the tenets of the declaration of Helsinki and was approved by the North Manchester Research Ethics committee. Informed written consent was obtained from all subjects before participation.
Clinical and Peripheral Neuropathy Assessment
All subjects underwent assessment of systolic and diastolic blood pressure, BMI, HbA 1c , lipid fractions (total cholesterol, LDL, HDL, and triglycerides), and estimated glomerular filtration rate. Signs and symptoms of neuropathy were assessed using the neuropathy symptom profile, neuropathy disability score, vibration perception threshold (VPT; Horwell Scientific Laboratory Supplies, Wilford, Nottingham, U.K.), and cool (CT) and warm (WT) thresholds (Medoc Ltd., Ramat-Yishai, Israel). Sural sensory nerve amplitude and conduction velocity, and peroneal motor nerve amplitude and conduction velocity were assessed. Heart rate variability deep breathing (HRVdb) was assessed with an ANX 3.0 autonomic nervous system monitoring device (ANSAR Medical Technologies Inc., Philadelphia, PA). Sudomotor function was assessed using Neuropad (miro Verbandstoffe, Wiehl-Drabenderhole, Germany).
Skin Biopsy
A 3-mm punch skin biopsy specimen was obtained from the dorsum of the foot ;2 cm above the second metatarsal head after local anesthesia (1% lidocaine), and IENFD was quantified in accord with established criteria (8) .
CCM
Patients underwent examination with CCM (Heidelberg Engineering GmbH, Heidelberg, Germany), and three established corneal nerve parametersdcorneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), and corneal nerve fiber length (CNFL)dwere quantified in a masked fashion, as previously described (9) .
Statistical Analysis
SPSS for Mac version 19.0 software (IBM Corp., Armonk, NY) was used for descriptive and frequency statistics. An unpaired t test (or nonparametric MannWhitney U test) was used to study differences between means. All data are expressed as mean 6 SEM, and a P , 0.05 was considered significant.
RESULTS
Clinical Assessment
Subjects with IGT and control subjects were matched for age. Subjects with IGT had a significantly greater 2-h glucose level for the oral glucose tolerance test (9.2 6 1.0 vs. 6.5 6 0.6 mmol/L, P = 0.001), and they had a higher BMI (31.7 6 1.0 vs. 27.9 6 1.2 kg/m 2 , P = 0.02) and HbA 1c (6.0 6 0.2/43.9 6 1.0 vs. 5.4 6 0.1/36.0 6 0.3 mmol/mol, P , 0.001), with a lower total (4.8 6 0.2 vs. 5.5 6 0.2 mmol/L, P = 0.02) and HDL (1.2 6 0.1 vs. 1.7 6 0.1 mmol/L, P , 0.001) cholesterol compared with control subjects. There was no difference in systolic/diastolic blood pressure (132/ 78 vs. 137/79 mmHg, P = 0.5), LDL cholesterol (2.1 6 1.1 vs. 3.2 6 0.6 mmol/L, P = 0.1), and triglycerides (2.8 6 1.0 vs. 1.7 6 0.9 mmol/L, P = 0.2).
Neuropathy Assessment
The neuropathy symptom profile (4.1 6 1.0 vs. 0.5 6 0.2, P , 0.001), the McGill pain index (2.8 6 0.3 vs. 0.2 6 0.1, P , 0.001), the neuropathy disability score (2.9 6 0.5 vs. 0.6 6 0.2, P = 0.001), VPT (15.9 6 2.3 vs. 6.5 6 1.1, P = 0.002), and WT (40.6 6 0.8 vs. 37.6 6 0.6, P = 0.006) were significantly increased, whereas CT (24.9 6 1.3 vs. 27.5 6 0.6, P = 0.03), neuropad response (71.0 6 2.8% vs. 93.0 6 5.6%, P = 0.05), IENFD (6.3 6 0.6 vs. 9.1 6 0.7, P = 0.03), CNFD (27.6 6 1.2 vs. 37.4 6 1.6, P , 0.001), CNBD (55.8 6 6.0 vs. 89.2 6 8.4, P = 0.02), and CNFL (22.1 6 1.2 vs. 25.7 6 1.2, P = 0.05) were significantly decreased in the IGT group compared with the control group (Fig. 1) . There was no significant difference in sural sensory nerve amplitude (14.0 6 1.4 vs. 16.6 6 1.9, P = 0.2) and conduction velocity (49.9 6 0.9 vs. 49.9 6 1.0, P = 0.8), in peroneal motor nerve amplitude (4.6 6 0.4 vs. 5.3 6 0.5, P = 0.1) and conduction velocity (45.6 6 0.7 vs. 47.5 6 0.7, P = 0.1), or in HRVdb (9.5 6 6.9 vs. 11.9 6 6.9, P = 0.09).
Under the assumption that CNFD is normally distributed in controls and IGT (Shapiro-Wilk W test, P . 0.05) and based on a cutoff point of 2 SD from the control average (CNFD = 24.0 no./mm 2 ), subjects with IGT were restratified into two groups: 22 without IGT neuropathy (IGTN; CNFD .24.0 no./mm 2 ) and 15 (40.5%) with IGTN (CNFD ,24.0 no./mm 2 ). There was significantly greater self-reported pain intensity (McGill Pain Index, P = 0.04) and reduction in CNBD (P = 0.02) and CNFL (P , 0.001) in subjects with IGTN compared with IGT (Fig. 1E) .
CONCLUSIONS
A recent study has shown a significant reduction in IENFD and abnormal corneal nerve morphology in patients with type 2 diabetes of short duration, suggesting that neuropathy may be an early complication (10), and of course, longitudinal data from the Rochester cohort (11) suggest that duration and severity of exposure to hyperglycemia are related to the severity of neuropathy. In the current study, we show a significant increase in neuropathic symptoms, consistent with the MONICA/KORA Augsburg Surveys (3), which also found a threefold increase in neuropathic pain in subjects with IGT. We also show a significant alteration in sudomotor function, whereas cardiac autonomic function and electrophysiology were normal, similar to a previous study in subjects with IGT demonstrating an abnormal sympathetic skin response but normal results on electrophysiology and standard autonomic function tests (12). These latter findings are similar to a large population-based study that also showed no electrodiagnostic abnormalities in subjects with impaired fasting glucose or IGT (4) . However, we demonstrate a significant abnormality in VPT, WT, and CT, similar to the San Luis Valley study (2) , which also reported impaired VPT in 11.2% of subjects with IGT compared with 3.5% in control subjects.
Previous studies have demonstrated a reduction in IENFD in subjects with IGT, which improved after lifestyle intervention (5), suggesting that this early abnormality may be amenable to treatment. We now confirm a significant reduction in IENFD in subjects with IGT. In addition, we also demonstrate a significant abnormality in corneal nerve morphology using the noninvasive technique of CCM and indeed show that 40.5% of subjects with IGT have significant small-fiber damage based on CNFD reduction. CCM provides a unique opportunity to noninvasively and rapidly assess unmyelinated C fibers in vivo, which has important diagnostic (6) and prognostic (8) implications. In conclusion, this study shows evidence of neuropathy in subjects with IGT, as evidenced by abnormal symptoms, signs, quantitative sensory testing, skin biopsy, and CCM, but not neurophysiology (13) . reviewed the manuscript and is a coinvestigator. M.T. researched data, reviewed the manuscript, and is a coinvestigator. R.A.M. designed the study, reviewed the manuscript, and is the principal investigator of the study. R.A.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
